Michael Quirmbach

Group Chief Executive Officer & President at Corden Pharma - A Full-Service CDMO

Basel, Basel, Switzerland

About

I am an open minded enthusiastic leader working >20 years in the CDMO industry - I am driven by science and technology to help to bring new medicines to patients.

Experience

  • Corden Pharma - A Full-Service CDMO (11 yrs 10 mos)
    • Group Chief Executive Officer & President
      Aug 2019 - Present · 7 yrs

    • Chief Business Officer
      Oct 2014 - Jul 2019 · 4 yrs 10 mos

  • Siegfried Holding AG (1 yr 8 mos)
    • VP Business Development, Head of Exclusives EU & ROW
      Apr 2014 - Sep 2014 · 6 mos

      The Siegfried Group is a global life sciences company, headquartered in Switzerland, with facilities located in Switzerland, the USA, Malta, China, Germany and France. In 2017, the company achieved net sales of CHF 750.5 million and currently employs approximately 2300 people. Siegfried Holding AG is publicly listed on the Swiss Stock Exchange in Zurich (SIX: SFZN). Siegfried is active in primary and secondary drug manufacturing. The company develops and manufactures active pharmaceutical ingredients for pharmaceutical clients with R&D programs, related intermediates and controlled substances. Siegfried also offers development and production of finished dosage forms, including sterile fillings.

    • Sr. Director Business Development
      Feb 2013 - Mar 2014 · 1 yr 2 mos

  • Sr. Manager Sales & Business Development / Technology Manager HPAPIs at Dr. Reddy's Laboratories
    Jun 2011 - Feb 2013 · 1 yr 9 mos

    Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe with major markets include – USA, India, Russia & CIS countries, and Europe. www.drreddys.com

  • Solvias AG (5 yrs 4 mos)
    • Head of Sales & Business Development, North America
      Jul 2010 - Jun 2011 · 1 yr

    • Business Development & Product Manager Synthesis & Catalysis
      Mar 2006 - Jun 2010 · 4 yrs 4 mos

  • Senior Scientist at Speedel Pharma AG
    Jan 2004 - Mar 2006 · 2 yrs 3 mos

    Speedel Pharma AG was acquired by Novartis AG in 2008 for USD 900M. Speedel Pharma AG developed drugs (focus on renin inhibitors such as Tekturna (Aliskiren)) for the treatment of cardiovascular and metabolic diseases. Tekturna is the first in a new class of drugs called direct renin inhibitors, which target an enzyme responsible for triggering a process that can contribute to high blood pressure. The company was founded in 1998 and is based in Basel, Switzerland.